Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio
BackgroundIn this post-hoc, exploratory analysis, we examined outcomes for patients enrolled in the AVAglio trial of front-line bevacizumab or placebo plus radiotherapy/temozolomide who received only a single line of therapy.MethodsPatients with newly diagnosed glioblastoma received protocol-defined...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 March 2016
|
| In: |
Neuro-Oncology
Year: 2016, Volume: 18, Issue: 9, Pages: 1313-1318 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/now046 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/neuonc/now046 Verlag, kostenfrei, Volltext: https://academic.oup.com/neuro-oncology/article/18/9/1313/2223057 
|
| Author Notes: | Olivier L. Chinot, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Timothy Cloughesy, Josep Garcia, Cedric Revil, Lauren Abrey, and Wolfgang Wick |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1568516010 | ||
| 003 | DE-627 | ||
| 005 | 20230427155641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180207s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/now046 |2 doi | |
| 035 | |a (DE-627)1568516010 | ||
| 035 | |a (DE-576)498516016 | ||
| 035 | |a (DE-599)BSZ498516016 | ||
| 035 | |a (OCoLC)1340986424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chinot, Olivier L. |e VerfasserIn |0 (DE-588)1084035049 |0 (DE-627)848243048 |0 (DE-576)456172289 |4 aut | |
| 245 | 1 | 0 | |a Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy |b an exploratory analysis of AVAglio |c Olivier L. Chinot, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Timothy Cloughesy, Josep Garcia, Cedric Revil, Lauren Abrey, and Wolfgang Wick |
| 264 | 1 | |c 22 March 2016 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.02.2018 | ||
| 520 | |a BackgroundIn this post-hoc, exploratory analysis, we examined outcomes for patients enrolled in the AVAglio trial of front-line bevacizumab or placebo plus radiotherapy/temozolomide who received only a single line of therapy.MethodsPatients with newly diagnosed glioblastoma received protocol-defined treatment until progressive disease (PD). Co-primary endpoints were investigator-assessed progression-free survival (PFS) and overall survival (OS). After confirmed PD, patients were treated at the investigators' discretion. PFS/OS were assessed in patients with a PFS event who did not receive post-PD therapy (Group 1) and patients with a PFS event who received post-PD therapy plus patients who did not have a PFS event at the final data cutoff (Group 2). Kaplan-Meier methodology was used. A multivariate Cox proportional hazards model for known prognostic variables was generated.ResultsBaseline characteristics were balanced. In patients with a PFS event who did not receive post-PD therapy (Group 1; n = 225 [24.4% of the intent-to-treat population]), the addition of bevacizumab to radiotherapy/temozolomide resulted in a 3.6-month extension in both median PFS (hazard ratio [HR]: 0.62, P = .0016) and median OS (HR: 0.67, P = .0102). Multivariate analyses supported this OS benefit (HR: 0.66). In the remaining patients (Group 2; n = 696), a 5.2-month PFS extension was observed in bevacizumab-treated patients (HR: 0.61, P < .0001); OS was comparable between the treatment arms (HR: 0.88, P = .1502). No significant differences in safety were observed between the 2 groups.ConclusionThis exploratory analysis suggests that the addition of bevacizumab to standard glioblastoma treatment prolongs PFS and OS for patients with PD who receive only one line of therapy. | ||
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-Oncology |d Oxford : Oxford Univ. Press, 1999 |g 18(2016), 9, Seite 1313-1318 |h Online-Ressource |w (DE-627)357167341 |w (DE-600)2094060-9 |w (DE-576)318041839 |x 1523-5866 |7 nnas |a Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy an exploratory analysis of AVAglio |
| 773 | 1 | 8 | |g volume:18 |g year:2016 |g number:9 |g pages:1313-1318 |g extent:6 |a Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy an exploratory analysis of AVAglio |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/neuonc/now046 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/neuro-oncology/article/18/9/1313/2223057 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180207 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 10 |y j | ||
| 999 | |a KXP-PPN1568516010 |e 2996247043 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Olivier L. Chinot, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Timothy Cloughesy, Josep Garcia, Cedric Revil, Lauren Abrey, and Wolfgang Wick"]},"id":{"eki":["1568516010"],"doi":["10.1093/neuonc/now046"]},"physDesc":[{"extent":"6 S."}],"recId":"1568516010","origin":[{"dateIssuedDisp":"22 March 2016","dateIssuedKey":"2016"}],"relHost":[{"disp":"Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy an exploratory analysis of AVAglioNeuro-Oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"357167341","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 21.07.23"],"id":{"eki":["357167341"],"issn":["1523-5866"],"zdb":["2094060-9"]},"title":[{"title_sort":"Neuro-Oncology","title":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology"}],"part":{"year":"2016","volume":"18","pages":"1313-1318","issue":"9","extent":"6","text":"18(2016), 9, Seite 1313-1318"},"origin":[{"publisher":"Oxford Univ. Press ; Duke University Medical Center","dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisherPlace":"Oxford ; Durham, NC"}],"pubHistory":["1.1999 -"]}],"person":[{"display":"Chinot, Olivier L.","role":"aut","given":"Olivier L.","family":"Chinot"},{"family":"Wick","given":"Wolfgang","role":"aut","display":"Wick, Wolfgang"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 07.02.2018"],"title":[{"subtitle":"an exploratory analysis of AVAglio","title":"Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy","title_sort":"Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy"}]} | ||
| SRT | |a CHINOTOLIVUPFRONTBEV2220 | ||